VEGF inhibitors

• 

Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?

By Sharon Deveson Kell|2022-06-08T10:36:43+00:008 Jun 2022|Drug treatments|

Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]

Read More

Comments Off on Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?

• 

Genetic biomarkers for the survival of kidney cancer patients

By Sharon Deveson Kell|2022-04-13T08:40:39+00:0013 Apr 2022|Drug treatments|

Previously, researchers found some genes that helped identify which patients [...]

Read More

Comments Off on Genetic biomarkers for the survival of kidney cancer patients

• 

International Kidney Cancer Symposium (IKCS) 2021

By Sharon Deveson Kell|2021-11-08T09:57:32+00:008 Nov 2021|Cancer news|

The International Kidney Cancer Symposium (IKCS) 2021 took place in [...]

Read More

Comments Off on International Kidney Cancer Symposium (IKCS) 2021

• 

SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland

By Sharon Deveson Kell|2021-10-13T14:59:32+00:0013 Oct 2021|Drug treatments|

The Scottish Medicines Consortium (SMC) has approved the use of [...]

Read More

Comments Off on SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland

• 

Pegilodecakin for metastatic kidney cancer

By Robert|2021-07-07T13:01:07+00:0025 Jun 2021|Drug treatments|

Combinations of immunotherapy and vascular endothelial growth factor (VEGF) inhibitors [...]

Read More

Comments Off on Pegilodecakin for metastatic kidney cancer

• 

ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer

By Robert|2021-07-07T12:44:15+00:007 Jun 2021|Drug treatments|

The cabozantinib/nivolumab combination has been shown to be effective at [...]

Read More

Comments Off on ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer

• 

EIKCS 2021: Future treatments for metastatic kidney cancer

By Robert|2021-07-07T11:46:13+00:0026 Apr 2021|Uncategorized|

Despite the advances in first-line treatments for metastatic renal cell [...]

Read More

Comments Off on EIKCS 2021: Future treatments for metastatic kidney cancer

• 

EIKCS 2021: Second-line and later treatments for metastatic kidney cancer

By Robert|2021-07-07T11:42:47+00:0026 Apr 2021|Drug treatments|

The increase in the number of first-line treatments for metastatic [...]

Read More

Comments Off on EIKCS 2021: Second-line and later treatments for metastatic kidney cancer

• 

EIKCS 2021: Combination therapies for metastatic kidney cancer: Which Approach?

By Robert|2021-07-07T11:39:52+00:0026 Apr 2021|Drug treatments|

The use of combination therapies for the first-line treatment of [...]

Read More

Comments Off on EIKCS 2021: Combination therapies for metastatic kidney cancer: Which Approach?

• 

Effectiveness of second-line sunitinib after immunotherapy in metastatic kidney cancer

By Robert|2021-07-07T11:37:50+00:0020 Apr 2021|Drug treatments|

There is very little information on the effectiveness of sunitinib [...]

Read More

Comments Off on Effectiveness of second-line sunitinib after immunotherapy in metastatic kidney cancer